Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate Cancer

Partner | Cancer Centers | <b>UCLA Health Jonsson Comprehensive Cancer Center</b>

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the rationale for creating the 68Ga-PSMA-11 PET imaging test in prostate cancer.

The 68Ga-PSMA-11 PET test, a whole-body scan for patients with prostate cancer, offers insight into tumor location and provides other relevant information in the clinical setting. Knowing the location of the tumor is vital for many available treatments for this disease, including radiation and surgery.

What had once been an unmet need in the prostate cancer paradigm has now been filled with the the development of the 68Ga-PSMA-11 PET imaging test; this test can help improve future prostate cancer regimens, concludes Fendler.